{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:19:29Z","timestamp":1793744369129,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103443"],"award-info":[{"award-number":["82103443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400531"],"award-info":[{"award-number":["32400531"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322008"],"award-info":[{"award-number":["82322008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ascites, a hallmark of advanced ovarian cancer, severely impairs patient quality of life and contributes to therapeutic resistance. Current management strategies remain primarily palliative, highlighting the urgent need to elucidate the underlying mechanisms. Although TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophages are enriched in malignant ascites, the role of soluble TREM2 (sTREM2) in regulating vascular function and ascites pathogenesis remains poorly understood. Here, we show that sTREM2 levels are elevated in malignant ascites and positively correlate with ascites volume. Using a combination of in vitro, in vivo, and ex vivo models, we demonstrate that sTREM2 promotes vascular permeability and drives ascites formation. Mechanistically, sTREM2 binds to nucleolin (NCL) on endothelial cells and activates the AKT\/eNOS signaling pathway, which leads to VE-cadherin phosphorylation and ultimately vascular leakage. sTREM2-induced hyperpermeability was abolished by NCL knockdown or eNOS inhibition. Importantly, administration of a neutralizing antibody against sTREM2 significantly reduced ascites formation and tumor burden in mouse models. Our study identifies the sTREM2-NCL-AKT-eNOS axis as a critical driver of vascular leakage and malignant ascites in ovarian cancer, highlighting it as a promising therapeutic target.\n                  <\/jats:p>","DOI":"10.1038\/s44321-026-00452-2","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:28:20Z","timestamp":1779805700000},"page":"2667-2690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Soluble TREM2 engages cell-surface nucleolin to drive vascular permeability and malignant ascites in ovarian cancer"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6919-5050","authenticated-orcid":false,"given":"Qianqian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-0237","authenticated-orcid":false,"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8390","authenticated-orcid":false,"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-8173","authenticated-orcid":false,"given":"Shuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7369-1310","authenticated-orcid":false,"given":"Bingfan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-0840","authenticated-orcid":false,"given":"Huanhuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/ijms231810692","volume":"23","author":"DL Almeida-Nunes","year":"2022","unstructured":"Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S (2022) Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci 23:2496","journal-title":"Int J Mol Sci"},{"key":"452_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0497-3","volume":"15","author":"I Bekes","year":"2016","unstructured":"Bekes I, Friedl TW, K\u00f6hler T, M\u00f6bus V, Janni W, W\u00f6ckel A, Wulff C (2016) Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer 15:13","journal-title":"Mol Cancer"},{"key":"452_CR3","first-page":"1567","volume":"369","author":"BA Benitez","year":"2013","unstructured":"Benitez BA, Cruchaga C (2013) TREM2 and neurodegenerative disease. N Engl J Med 369:1567\u20131568","journal-title":"N Engl J Med"},{"key":"452_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102646","volume":"121","author":"JM Berger","year":"2023","unstructured":"Berger JM, Preusser M, Berghoff AS, Bergen ES (2023) Malignant ascites: current therapy options and treatment prospects. Cancer Treat Rev 121:102646","journal-title":"Cancer Treat Rev"},{"key":"452_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, Jahchan NS, Canaday P, Lu E, Norng M et al (2021) Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep 37:109844","journal-title":"Cell Rep"},{"key":"452_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.834697","volume":"13","author":"GC Brown","year":"2021","unstructured":"Brown GC, St George-Hyslop P (2021) Does Soluble TREM2 protect against Alzheimer\u2019s disease? Front Aging Neurosci 13:834697","journal-title":"Front Aging Neurosci"},{"key":"452_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Zhu T, Jiang G, Zeng Q, Li Z, Huang X (2023) Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol Cancer 22:131","journal-title":"Mol Cancer"},{"key":"452_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57024-0","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui H, Banerjee S, Xie N, Hussain M, Jaiswal A, Liu H, Kulkarni T, Antony VB, Liu RM, Colonna M et al (2025) TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nat Commun 16:1761","journal-title":"Nat Commun"},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaci.2013.07.026","volume":"132","author":"H Cui","year":"2013","unstructured":"Cui H, Okamoto Y, Yoshioka K, Du W, Takuwa N, Zhang W, Asano M, Shibamoto T, Takuwa Y (2013) Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice. J Allergy Clin Immunol 132:1205\u20131214.e9","journal-title":"J Allergy Clin Immunol"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska A, Weiner A, Amit I (2020) The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181:1207\u20131217","journal-title":"Cell"},{"key":"452_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105630","volume":"165","author":"F Filipello","year":"2022","unstructured":"Filipello F, Goldsbury C, You SF, Locca A, Karch CM, Piccio L (2022) Soluble TREM2: Innocent bystander or active player in neurological diseases? Neurobiol Dis 165:105630","journal-title":"Neurobiol Dis"},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K (2020) The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 123:9\u201316","journal-title":"Br J Cancer"},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2024.10.002","volume":"275","author":"X Gu","year":"2025","unstructured":"Gu X, Kang H, Cao S, Tong Z, Song N (2025) Blockade of TREM2 ameliorates pulmonary inflammation and fibrosis by modulating sphingolipid metabolism. Transl Res 275:1\u201317","journal-title":"Transl Res"},{"key":"452_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963373","volume":"13","author":"T Guo","year":"2022","unstructured":"Guo T, Ma J, Sun J, Xu W, Cong H, Wei Y, Ma Y, Dong Q, Kou Y, Yin L et al (2022) Soluble TREM2 is a potential biomarker for the severity of primary angiitis of the CNS. Front Immunol 13:963373","journal-title":"Front Immunol"},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","volume":"77","author":"T Hendrikx","year":"2022","unstructured":"Hendrikx T, Porsch F, Kiss MG, Rajcic D, Papac-Mili\u010devi\u0107 N, Hoebinger C, Goederle L, Hladik A, Shaw LE, Horstmann H et al (2022) Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH. J Hepatol 77:1373\u20131385","journal-title":"J Hepatol"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"e135197","DOI":"10.1172\/JCI135197","volume":"131","author":"J Hou","year":"2021","unstructured":"Hou J, Zhang J, Cui P, Zhou Y, Liu C, Wu X, Ji Y, Wang S, Cheng B, Ye H et al (2021) TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J Clin Invest 131:e135197","journal-title":"J Clin Invest"},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2017.07.025","volume":"186","author":"W Jia","year":"2017","unstructured":"Jia W, Yao Z, Zhao J, Guan Q, Gao L (2017) New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci 186:1\u201310","journal-title":"Life Sci"},{"key":"452_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04618-x","volume":"13","author":"DC Kirman","year":"2022","unstructured":"Kirman DC, Renganathan B, Chui WK, Chen MW, Kaya NA, Ge R (2022) Cell surface nucleolin is a novel ADAMTS5 receptor mediating endothelial cell apoptosis. Cell Death Dis 13:172","journal-title":"Cell Death Dis"},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA (2023) Clinical and translational advances in ovarian cancer therapy. Nat Cancer 4:1239\u20131257","journal-title":"Nat Cancer"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/ijmm.2024.5387","volume":"54","author":"N Li","year":"2024","unstructured":"Li N, Yi Y, Chen J, Huang Y, Peng J, Li Z, Wang Y, Zhang J, Xu C, Liu H et al (2024) Anthrahydroquinone\u20112,6\u2011disulfonate attenuates PQ\u2011induced acute lung injury through decreasing pulmonary microvascular permeability via inhibition of the PI3K\/AKT\/eNOS pathway. Int J Mol Med 54:63","journal-title":"Int J Mol Med"},{"key":"452_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154833","volume":"115","author":"G Liu","year":"2023","unstructured":"Liu G, Wang J, Han M, Li X, Zhou L, Dou T, Liu Y, HuangFu M, Guan X, Wang Y et al (2023) RNA-binding domain 2 of nucleolin is important for the autophagy induction of curcumol in nasopharyngeal carcinoma cells. Phytomedicine 115:154833","journal-title":"Phytomedicine"},{"key":"452_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/cac2.12330","volume":"42","author":"H Lou","year":"2022","unstructured":"Lou H, Cao X (2022) Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun 42:804\u2013827","journal-title":"Cancer Commun"},{"key":"452_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411314","volume":"12","author":"H Luo","year":"2025","unstructured":"Luo H, She X, Zhang Y, Xie B, Zhang S, Li Q, Zhou Y, Guo S, Zhang S, Jiang Y et al (2025) PLIN2 promotes lipid accumulation in ascites-associated macrophages and ovarian cancer progression by HIF1\u03b1\/SPP1 signaling. Adv Sci 12:e2411314","journal-title":"Adv Sci"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdw306","volume":"27","author":"M Malvezzi","year":"2016","unstructured":"Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C (2016) Global trends and predictions in ovarian cancer mortality. Ann Oncol 27:2017\u20132025","journal-title":"Ann Oncol"},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","volume":"31","author":"S Masoumi Moghaddam","year":"2012","unstructured":"Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH (2012) Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31:143\u2013162","journal-title":"Cancer Metastasis Rev"},{"key":"452_CR26","doi-asserted-by":"publisher","first-page":"e159400","DOI":"10.1172\/JCI159400","volume":"135","author":"S Ming","year":"2024","unstructured":"Ming S, Li X, Xiao Q, Qu S, Wang Q, Fang Q, Liang P, Xu Y, Yang J, Yang Y et al (2024) TREM2 aggravates sepsis by inhibiting fatty acid oxidation via the SHP1\/BTK axis. J Clin Invest 135:e159400","journal-title":"J Clin Invest"},{"key":"452_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101739","volume":"67","author":"M Molgora","year":"2023","unstructured":"Molgora M, Liu YA, Colonna M, Cella M (2023) TREM2: a new player in the tumor microenvironment. Semin Immunol 67:101739","journal-title":"Semin Immunol"},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.semcancer.2022.03.004","volume":"86","author":"M Monavarian","year":"2022","unstructured":"Monavarian M, Elhaw AT, Tang PW, Javed Z, Shonibare Z, Scalise CB, Arend R, Jolly MK, Sewell-Loftin MK, Hempel N et al (2022) Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment. Semin Cancer Biol 86:709\u2013719","journal-title":"Semin Cancer Biol"},{"key":"452_CR29","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","volume":"27","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Minion LE, Coleman RL (2016) Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27:i33\u2013i39","journal-title":"Ann Oncol"},{"key":"452_CR30","doi-asserted-by":"publisher","first-page":"x53","DOI":"10.1093\/annonc\/mdt472","volume":"24","author":"BJ Monk","year":"2013","unstructured":"Monk BJ, Pujade-Lauraine E, Burger RA (2013) Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. Ann Oncol 24:x53\u2013x58","journal-title":"Ann Oncol"},{"key":"452_CR31","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","volume":"75","author":"DL Moughon","year":"2015","unstructured":"Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O, Wu L (2015) Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res 75:4742\u20134752","journal-title":"Cancer Res"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-020-00356-8","volume":"5","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ (2020) TREM2 marks tumor-associated macrophages. Signal Transduct Target Ther 5:233","journal-title":"Signal Transduct Target Ther"},{"key":"452_CR33","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1172\/JCI77983","volume":"125","author":"PL Poliani","year":"2015","unstructured":"Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M (2015) TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125:2161\u20132170","journal-title":"J Clin Invest"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/brain\/awad321","volume":"147","author":"C Qin","year":"2024","unstructured":"Qin C, Chen M, Dong MH, Yang S, Zhang H, You YF, Zhou LQ, Chu YH, Tang Y, Pang XW et al (2024) Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders. Brain 147:163\u2013176","journal-title":"Brain"},{"key":"452_CR35","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G, Polacheck WJ, Roque DM et al (2021) Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers 13:4318","journal-title":"Cancers"},{"key":"452_CR36","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1074\/mcp.M114.041194","volume":"13","author":"VO Shender","year":"2014","unstructured":"Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, Altukhov IA, Alexeev DG, Butenko IO, Shavarda AL et al (2014) Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics 13:3558\u20133571","journal-title":"Mol Cell Proteomics"},{"key":"452_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06606-2","volume":"9","author":"SH Shin","year":"2018","unstructured":"Shin SH, Lee GY, Lee M, Kang J, Shin HW, Chun YS, Park JW (2018) Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway. Nat Commun 9:4113","journal-title":"Nat Commun"},{"key":"452_CR38","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics. CA Cancer J Clin 75:10\u201345","journal-title":"CA Cancer J Clin"},{"key":"452_CR39","doi-asserted-by":"publisher","first-page":"e161366","DOI":"10.1172\/JCI161366","volume":"133","author":"E Sj\u00f6berg","year":"2023","unstructured":"Sj\u00f6berg E, Melssen M, Richards M, Ding Y, Chanoca C, Chen D, Nwadozi E, Pal S, Love DT, Ninchoji T et al (2023) Endothelial VEGFR2-PLC\u03b3 signaling regulates vascular permeability and antitumor immunity through eNOS\/Src. J Clin Invest 133:e161366","journal-title":"J Clin Invest"},{"key":"452_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10456-012-9284-y","volume":"15","author":"N Song","year":"2012","unstructured":"Song N, Ding Y, Zhuo W, He T, Fu Z, Chen Y, Song X, Fu Y, Luo Y (2012) The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells. Angiogenesis 15:697\u2013711","journal-title":"Angiogenesis"},{"key":"452_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1023\/A:1012504904713","volume":"12","author":"JT Tamsma","year":"2001","unstructured":"Tamsma JT, Keizer HJ, Meinders AE (2001) Pathogenesis of malignant ascites: Starling\u2019s law of capillary hemodynamics revisited. Ann Oncol 12:1353\u20131357","journal-title":"Ann Oncol"},{"key":"452_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","volume":"17","author":"KE Tiller","year":"2015","unstructured":"Tiller KE, Tessier PM (2015) Advances in antibody design. Annu Rev Biomed Eng 17:191\u2013216","journal-title":"Annu Rev Biomed Eng"},{"key":"452_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00018-022-04300-7","volume":"79","author":"F Tonello","year":"2022","unstructured":"Tonello F, Massimino ML, Peggion C (2022) Nucleolin: a cell portal for viruses, bacteria, and toxins. Cell Mol Life Sci 79:271","journal-title":"Cell Mol Life Sci"},{"key":"452_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jare.2024.08.029","volume":"73","author":"L Xu","year":"2025","unstructured":"Xu L, Ma W, Huo X, Luo J, Li R, Zhu X, Kong X, Zhao K, Jin Y, Zhang M et al (2025) New insights into the function and mechanisms of piRNA PMLCPIR in promoting PM(2.5)-induced lung cancer. J Adv Res 73:659\u2013670","journal-title":"J Adv Res"},{"key":"452_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113750","volume":"145","author":"P Yin","year":"2025","unstructured":"Yin P, Jiang H, Ji X, Xia L, Su Z, Tian Y (2025) Soluble TREM2 drives triple-negative breast cancer progression via activation of the AKT pathway. Int Immunopharmacol 145:113750","journal-title":"Int Immunopharmacol"},{"key":"452_CR46","doi-asserted-by":"publisher","first-page":"e140315","DOI":"10.1172\/JCI140315","volume":"131","author":"S Zhang","year":"2021","unstructured":"Zhang S, Xie B, Wang L, Yang H, Zhang H, Chen Y, Wang F, Liu C, He H (2021) Macrophage-mediated vascular permeability via VLA4\/VCAM1 pathway dictates ascites development in ovarian cancer. J Clin Invest 131:e140315","journal-title":"J Clin Invest"},{"key":"452_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42505-x","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Tang L, Yang J, Meng L, Chen J, Zhou L, Wang J, Xiong M, Zhang Z (2023) Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer\u2019s disease. Nat Commun 14:6670","journal-title":"Nat Commun"},{"key":"452_CR48","doi-asserted-by":"publisher","first-page":"e158708","DOI":"10.1172\/JCI158708","volume":"132","author":"A Zhao","year":"2022","unstructured":"Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, Deng Y, Liu J (2022) Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Clin Invest 132:e158708","journal-title":"J Clin Invest"},{"key":"452_CR49","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang X, Cheng X, Liu Z, Yin Y, Li X, Huang Z, Wang Z, Guo W, Ginhoux F et al (2023) Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat Cancer 4:1138\u20131156","journal-title":"Nat Cancer"},{"key":"452_CR50","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2024.05.001","volume":"42","author":"J Zhong","year":"2024","unstructured":"Zhong J, Xing X, Gao Y, Pei L, Lu C, Sun H, Lai Y, Du K, Xiao F, Yang Y et al (2024) Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer Cell 42:968\u2013984.e9","journal-title":"Cancer Cell"},{"key":"452_CR51","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1084\/jem.20160844","volume":"214","author":"L Zhong","year":"2017","unstructured":"Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X, Wu L et al (2017) Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med 214:597\u2013607","journal-title":"J Exp Med"},{"key":"452_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09118-9","volume":"10","author":"L Zhong","year":"2019","unstructured":"Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X et al (2019) Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer\u2019s disease model. Nat Commun 10:1365","journal-title":"Nat Commun"},{"key":"452_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jare.2022.03.011","volume":"44","author":"H Zhou","year":"2023","unstructured":"Zhou H, Li J, Hu L, Yu J, Fu X, Liang F, Yan F, Chen G (2023) Soluble Trem2 is a negative regulator of erythrophagocytosis after intracerebral hemorrhage in a CD36 receptor recycling manner. J Adv Res 44:185\u2013199","journal-title":"J Adv Res"},{"key":"452_CR54","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/path.2760","volume":"222","author":"W Zhuo","year":"2010","unstructured":"Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y (2010) Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 222:249\u2013260","journal-title":"J Pathol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00452-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:02:28Z","timestamp":1790600548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00452-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,13]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00452-2","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author contribution has been updated to correctly reflect the contribution of the first four authors.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}